Diamedica Therapeutics Inc SEC Filings

DiaMedica Therapeutics Inc. reported an update on its DM199 preeclampsia program following a pre-IND meeting with the U.S. Food and Drug Administration. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model before proceeding with the planned study of DM199 in preeclampsia. Preparations for this new rabbit study have begun and results are expected to be available by the second quarter of 2026.

The company reiterates forward-looking statements about the potential clinical benefits of DM199 for preeclampsia and acute ischemic stroke, and notes that outcomes depend on future non-clinical and clinical results, regulatory feedback, funding, and operational factors such as site activation and enrollment in trials.

DiaMedica Therapeutics Inc. (DMAC) director reports stock option exercise. A company director exercised a stock option to acquire 12,000 common shares of DiaMedica on 11/21/2025 at an exercise price of $2.20 per share, with the price shown after converting the original CAD$ exercise price to US$ on the transaction date. Following this transaction, the director directly owns 87,854 common shares of DiaMedica. The derivative position reported was a stock option (right to buy) for 12,000 shares that was fully vested and, after the exercise, the number of derivative securities beneficially owned is reported as 0.

DiaMedica Therapeutics Inc. (DMAC) filed a Form S-8 registering 1,000,000 common shares for issuance under its 2021 Employment Inducement Incentive Plan.

The Board amended the plan on July 31, 2025 to reserve an additional 1,000,000 shares for equity awards to individuals who were not previously employees or directors, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4). The plan allows stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock-based awards.

DiaMedica Therapeutics (DMAC) filed its Q3 2025 10-Q, highlighting a clinical-stage focus on DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). For the nine months ended September 30, 2025, the company reported a net loss of $24.0 million and used $21.3 million in operating cash. As of September 30, 2025, cash, cash equivalents and marketable securities were $55.3 million, with working capital of $51.0 million.

R&D expenses were $6.4 million in Q3 (up from $5.0 million a year ago) and G&A was $2.6 million (up from $1.9 million), reflecting ongoing ReMEDy2 trial activities and PE program work. The company completed a July 2025 private placement of 8,606,425 shares at $3.50 for $30.1 million gross (~$30.0 million net) and sold 223,472 shares via its ATM for $1.6 million gross; up to $100 million may be sold under the ATM, with $98.4 million remaining as of quarter end.

In PE, interim Phase 2 results (N=28) showed DM199 appeared safe with blood pressure reductions. In AIS, ReMEDy2 site activations and enrollment remain slower than expected; interim analysis is estimated in the second half of 2026, and UK approval to conduct the study was received on August 28, 2025.

DiaMedica Therapeutics (DMAC) reported a Form 4 for its Chief Marketing Officer showing a grant of stock options to purchase 450,000 shares at an exercise price of $4.58 per share on 08/11/2025. The options expire on 08/10/2035 and were reported as directly owned following the transaction.

The filing states a time-based vesting schedule: 112,500 options vest on the one-year anniversary of the grant date, and the remaining 337,500 vest in twelve equal quarterly installments starting three months after that one-year mark, conditioned on continued service.

DiaMedica Therapeutics Inc. (DMAC) filed a Form 3 initial statement of beneficial ownership for its Chief Marketing Officer. The filing states that no securities are beneficially owned. The event date was 08/11/2025.

The form was signed by attorney-in-fact Joshua L. Colburn pursuant to a Power of Attorney. This is a routine administrative disclosure and does not report any transactions.

Insider purchases increased a single beneficial stake to 7,764,465 shares of DiaMedica Therapeutics (DMAC). From August 13 to August 27, 2025, a series of open-market purchases totaling multiple transactions were reported, with individual purchase sizes ranging from 8,233 to 338,265 shares at per-share prices between $5.8573 and $6.00. The shares are owned directly by Trill AB and indirectly by Jan Stahlberg, a company director and 10% owner, who "has the sole power to vote and dispose" of the shares. The Form 4 shows continued accumulation over a two-week period via multiple purchases, and the filing is signed by Jan Stahlberg and by him as Board Member of Trill AB.

DiaMedica Therapeutics Inc. Schedule 13G/A shows that Trill AB and its board member Jan Stahlberg report beneficial ownership of 7,764,465 common shares, representing 15.02% of DiaMedica's outstanding common stock (based on 51,688,913 shares outstanding as of August 8, 2025). The filing identifies Trill AB as the record holder and Mr. Stahlberg as a beneficial owner and board member. The reported holdings reflect shared voting and shared dispositive power of 7,764,465 shares for each reporting person, with no sole voting or dispositive power. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.

DiaMedica Therapeutics Inc. (DMAC) received a Schedule 13G disclosing that Leon G. Cooperman may be deemed the beneficial owner of 3,110,220 Voting Common Shares, representing approximately 6.0% of the company's outstanding common shares. That total comprises 2,450,000 shares held directly by Mr. Cooperman and 660,220 shares held directly by The Leon and Toby Cooperman Foundation.

The filing states the ownership percentage is calculated using 51,688,913 shares outstanding as of August 8, 2025, per the issuer's quarterly report. The statement affirms the shares were not acquired to change or influence control of the issuer and lists Edward Levy signing as attorney-in-fact on behalf of Mr. Cooperman.